Supplementary Table 1: Budapest Research criteria



Supplementary Table 1: Budapest Research criteria

|(1) Continuing pain, which is disproportionate to any inciting event |

|(2) Must report at least one symptom in each of the four following categories: |

|– Sensory: reports of hyperesthesia and/or allodynia |

|– Vasomotor: reports of temperature asymmetry and/or skin color changes and/or skin color asymmetry |

|– Sudomotor/edema: reports of edema and/or sweating changes and/or sweating |

|asymmetry |

|– Motor/trophic: reports of decreased range of motion and/or motor dysfunction |

|(weakness, tremor, dystonia) and/or trophic changes (hair, nail, skin) |

| (3) Must display at least one sign at time of evaluation in two or more of the following categories: |

|– Sensory: evidence of hyperalgesia (to pinprick) and/or allodynia (to light touch and/or deep somatic pressure and/or joint movement) |

|– Vasomotor: evidence of temperature asymmetry and/or skin color changes and/or asymmetry |

|– Sudomotor/edema: evidence of edema and/or sweating changes and/or sweating asymmetry |

|– Motor/trophic: evidence of decreased range of motion and/or motor dysfunction (weakness, tremor, dystonia) and/or trophic changes |

|(hair, nail, skin) |

|(4) There is no other diagnosis that better explains the signs and symptoms |

Supplementary Table 2: Secondary analysis - Odds ratios and P-values estimated for HLA-A alleles typed among CRPS cases and control subjects.

|HLA-A alleles |Serotype |% Cases |% Controls |OR |95% CI |P |Pc |

|A*01 |A1 |34 |34 |1.04 |[0.72 – 1.49] |0.852 |1.000 |

|A*02 |A2 |44 |49 |0.80 |[0.57 – 1.14] |0.250 |0.997 |

|Primary analysis | | | | | | |

|B*15:01 |B62 |18 |15 |1.22 |[0.78 – 1.92] |0.458 | |

| | | | | | | | |

|Secondary analysis | | | | | | |

|B*07 |B7 |24 |25 |0.95 |[0.63 – 1.42] |0.838 |1.000 |

|B*08 |B8 |27 |26 |1.07 |[0.72 – 1.58] |0.762 |1.000 |

|C*01 |Cw1 |7 |6 |1.27 |[0.65 – 2.47 ] |0.568 |1.000 |

|C*02 |Cw2 |8 |10 |0.83 |[0.45 – 1.54] |0.561 |1.000 |

|DRB1*01 |DR1 |18 |22 |0.77 |[0.49 – 1.20] |0.241 |0.979 |

|DRB1*03:01 |DR17 |26 |28 |0.93 |[0.63 – 1.37] |0.767 |1.000 |

|Primary analysis | | | | | | |

|DQB1*03:02 |DQ8 |28 |19 |1.65 |[1.12 – 2.42] |0.014 | |

| | | | | | | |

|Secondary analysis | | | | | | |

|DQB1*02 |DQ2 |37 |39 |0.93 |[0.65 – 1.32] |0.718 |1.000 |

|DQB1*03:01 |DQ7 |37 |30 |

|HLA-DQ8 |0.65 (0.22) |1.91 (1.23-2.95) |0.00379 |

|Age |0.23 (0.02) |1.26 (1.22-1.29) | ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download